Literature DB >> 505347

Tuberculin reactivity as a predictor of survival time in inoperable bronchial carcinoma.

N J Snell.   

Abstract

One hundred and two patients with inoperable bronchial carcinoma who had tuberculin tests at the time of diagnosis were followed up to see if there was any correlation between their degree of tuberculin reactivity and their subsequent survival time. There was a significant difference in survival between positive and negative tuberculin reactors (Log Rank Test P less than 0.05), the former having a median survival time almost twice that of the latter. This did not appear to be related to clinical differences between the groups at the time of testing, and other possible explanations are discussed. Tuberculin testing may be useful in helping to assess prognosis in patients with inoperable bronchial tumours.

Entities:  

Mesh:

Year:  1979        PMID: 505347      PMCID: PMC471106          DOI: 10.1136/thx.34.4.508

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  9 in total

1.  Impaired lymphocyte responses to PPD-tuberculin in advanced breast carcinoma. Increased reactivity after depletion of phagocytic or adherent cells.

Authors:  H Blomgren; E Baral; B Petrini; J Wasserman
Journal:  Clin Oncol       Date:  1976-12

2.  An assessment of the carcinogenicity of isoniazid in patients with pulmonary tuberculosis.

Authors:  H Stott; J Peto; R Stephens; W Fox
Journal:  Tubercle       Date:  1976-03

3.  Prognosis of early bronchogenic carcinoma. Survival curves of 451 patients after resection of lung cancer in relation to the results of pre-operative tuberculin skin test.

Authors:  L Israel; J Mugica; P Chahinian
Journal:  Biomedicine       Date:  1973-02-10

4.  Relationship between tumor doubling time and anatomoclinical features in 50 measurable pulmonary cancers.

Authors:  P Chahinian
Journal:  Chest       Date:  1972-04       Impact factor: 9.410

5.  Diagnosis of lung cancer in tuberculous patients. Use of tuberculin skin test and serum protein electrophoresis.

Authors:  L I Bonchek
Journal:  Chest       Date:  1971-09       Impact factor: 9.410

6.  Immunologic alterations in bronchogenic cancer. Sequential study.

Authors:  M J Krant; G Manskopf; C S Brandrup; M A Madoff
Journal:  Cancer       Date:  1968-04       Impact factor: 6.860

7.  [Contribution to the study of phenomena of cellular immunity in pulmonary cancer before palliative or surgical treatment].

Authors:  L Israel; A Bouvrain; J Cros-Decam; J Mugica
Journal:  Poumon Coeur       Date:  1968

8.  Suppression of the tuberculin response in malignant disease.

Authors:  L E Hughes; W D Mackay
Journal:  Br Med J       Date:  1965-12-04

9.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

  9 in total
  2 in total

Review 1.  The management of lung cancer.

Authors:  S G Spiro
Journal:  Lung       Date:  1982       Impact factor: 2.584

2.  In vitro monocyte maturation as a prediction of survival in squamous cell carcinoma of the lung.

Authors:  R G Dent; P Cole
Journal:  Thorax       Date:  1981-06       Impact factor: 9.139

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.